{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:12:23Z","timestamp":1790835143183,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007927","name":"University of Oklahoma Health Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019803","name":"Center for Health Sciences, Oklahoma State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejphar.2024.176329","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T23:21:24Z","timestamp":1705792884000},"page":"176329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT2A receptor activation"],"prefix":"10.1016","volume":"966","author":[{"given":"Hugo R.","family":"Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-9732","authenticated-orcid":false,"given":"Deborah","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin J.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-5777","authenticated-orcid":false,"given":"Alican","family":"Gulsevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5881-6550","authenticated-orcid":false,"given":"Dina","family":"Manetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Anouar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"De Deurwaerdere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-193X","authenticated-orcid":false,"given":"Jens","family":"Meiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5685-3403","authenticated-orcid":false,"given":"Maria Novella","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2875-2453","authenticated-orcid":false,"given":"Abdeslam","family":"Chagraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176329_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175454","article-title":"(+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission","volume":"939","author":"Arias","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176329_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175854","article-title":"Coronaridine congeners induce sedative and anxiolytic-like activity in naive and stressed\/anxious mice by allosteric mechanisms involving increased GABA(A) receptor affinity for GABA","volume":"953","author":"Arias","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176329_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109930","article-title":"Coronaridine congeners potentiate GABA(A) receptors and induce sedative activity in mice in a benzodiazepine-insensitive manner","volume":"101","author":"Arias","year":"2020","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2024.176329_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108194","article-title":"Coronaridine congeners decrease neuropathic pain in mice and inhibit alpha9alpha10 nicotinic acetylcholine receptors and Ca(V)2.2 channels","volume":"175","author":"Arias","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2024.176329_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s42003-022-03643-y","article-title":"Hypnotic enhancement of slow-wave sleep increases sleep-associated hormone secretion and reduces sympathetic predominance in healthy humans","volume":"5","author":"Besedovsky","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejphar.2024.176329_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/11631890-000000000-00000","article-title":"Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine","volume":"32","author":"Bose","year":"2012","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejphar.2024.176329_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","article-title":"5-HT2ARs mediate therapeutic behavioral effects of psychedelic Tryptamines","volume":"14","author":"Cameron","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176329_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.176329_bib9","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1016\/j.neuron.2022.08.006","article-title":"Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD","volume":"110","author":"Cao","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2024.176329_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2024.176329_bib11","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.176329_bib12","volume":"vol. 2019","author":"Case","year":"2019"},{"key":"10.1016\/j.ejphar.2024.176329_bib13","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1111\/bph.15756","article-title":"A new class of 5-HT(2A)\/5-HT(2C) receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2-aminotetralins","volume":"179","author":"Casey","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176329_bib14","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176329_bib15","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41598-021-81552-6","article-title":"Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT(2A) receptor activation","volume":"11","author":"Contreras","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2024.176329_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26092451","article-title":"Molecular and functional imaging studies of psychedelic drug action in animals and humans","volume":"26","author":"Cumming","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2024.176329_bib17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41398-021-01430-7","article-title":"Opposite alterations of 5-HT(2A) receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile","volume":"11","author":"Diez-Alarcia","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2024.176329_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pro.2267","article-title":"Cryo-EM model validation using independent map reconstructions","volume":"22","author":"DiMaio","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejphar.2024.176329_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881120986422","article-title":"Hallucinogenic\/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action","volume":"35","author":"Dos Santos","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2024.176329_bib20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176329_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-009-1694-1","article-title":"The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis","volume":"212","author":"Fox","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2024.176329_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonzalez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2024.176329_bib23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/1073858410377064","article-title":"Slow wave activity during sleep: functional and therapeutic implications","volume":"16","author":"Greene","year":"2010","journal-title":"Neuroscientist"},{"key":"10.1016\/j.ejphar.2024.176329_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2024.176329_bib25","doi-asserted-by":"crossref","DOI":"10.1063\/5.0019056","article-title":"A fast and high-quality charge model for the next generation general AMBER force field","volume":"153","author":"He","year":"2020","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejphar.2024.176329_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/psymed.2023.0009","article-title":"Tabernanthalog reduces Motivation for Heroin and Alcohol in a Polydrug Use model","volume":"1","author":"Heinsbroek","year":"2023","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"10.1016\/j.ejphar.2024.176329_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2024.176329_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.750554","article-title":"Comparative assessment of TSPO modulators on electroencephalogram activity and exploratory behavior","volume":"13","author":"Hines","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176329_bib29","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41467-018-05481-1","article-title":"Developmental seizures and mortality result from reducing GABA(A) receptor alpha2-subunit interaction with collybistin","volume":"9","author":"Hines","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.176329_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2024.176329_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects","volume":"45","author":"Holze","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2024.176329_bib32","doi-asserted-by":"crossref","DOI":"10.1063\/1.4960175","article-title":"Accuracy limit of rigid 3-point water models","volume":"145","author":"Izadi","year":"2016","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejphar.2024.176329_bib33","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejphar.2024.176329_bib34","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00213-022-06092-x","article-title":"Effects of the 5-HT(2A) receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents","volume":"239","author":"Jaster","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2024.176329_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0301-0082(01)00016-8","article-title":"Behavioral arrest: in search of the neural control system","volume":"65","author":"Klemm","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2024.176329_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.102.042184","article-title":"Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves","volume":"304","author":"Kurrasch-Orbaugh","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176329_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.smrv.2018.01.008","article-title":"Slow-wave sleep: from the cell to the clinic","volume":"41","author":"Leger","year":"2018","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.ejphar.2024.176329_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2022.01.113","article-title":"G(s) signaling pathway distinguishes hallucinogenic and nonhallucinogenic 5-HT(2A)R agonists induced head twitch response in mice","volume":"598","author":"Liu","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2024.176329_bib39","doi-asserted-by":"crossref","first-page":"D370","DOI":"10.1093\/nar\/gkr703","article-title":"OPM database and PPM web server: resources for positioning of proteins in membranes","volume":"40","author":"Lomize","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2024.176329_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT(2A) receptor-mediated signaling pathways","volume":"36","author":"Lopez-Gimenez","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.ejphar.2024.176329_bib41","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1038\/s41380-021-01159-1","article-title":"An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress","volume":"26","author":"Lu","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2024.176329_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2017.07.012","article-title":"Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)","volume":"134","author":"Luethi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2024.176329_bib43","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/17425255.2021.1944099","article-title":"Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse","volume":"17","author":"Luz","year":"2021","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejphar.2024.176329_bib44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/prot.21086","article-title":"ROSETTALIGAND: protein-small molecule docking with full side-chain flexibility","volume":"65","author":"Meiler","year":"2006","journal-title":"Proteins"},{"key":"10.1016\/j.ejphar.2024.176329_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/acs.jcim.0c01140","article-title":"BCL::Conf: improved open-source knowledge-based conformation sampling using the crystallography open database","volume":"61","author":"Mendenhall","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejphar.2024.176329_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","article-title":"Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists","volume":"493","author":"Moreno","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2024.176329_bib47","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/jpet.106.117507","article-title":"Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors","volume":"321","author":"Moya","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176329_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.neuropharm.2014.08.009","article-title":"Evaluation of 5-HT2A and mGlu2\/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment","volume":"86","author":"Muguruza","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2024.176329_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euroneuro.2020.05.004","article-title":"Pimavanserin exhibits serotonin 5-HT(2A) receptor inverse agonism for G(alphai1)- and neutral antagonism for G(alphaq\/11)-proteins in human brain cortex","volume":"36","author":"Muneta-Arrate","year":"2020","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejphar.2024.176329_bib50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2024.176329_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biopsycho.2008.04.005","article-title":"Worry, generalized anxiety disorder, and emotion: evidence from the EEG gamma band","volume":"79","author":"Oathes","year":"2008","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.ejphar.2024.176329_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.neuroimage.2019.06.053","article-title":"Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives","volume":"200","author":"Pallavicini","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejphar.2024.176329_bib53","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41386-022-01324-2","article-title":"Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice","volume":"47","author":"Pedzich","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2024.176329_bib54","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1021\/acschemneuro.0c00152","article-title":"A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats","volume":"11","author":"Rodriguez","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176329_bib55","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejphar.2024.176329_bib56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.115.228148","article-title":"Directly observable behavioral effects of lorcaserin in rats","volume":"355","author":"Serafine","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176329_bib57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.31887\/DCNS.2011.13.2\/jsherin","article-title":"Post-traumatic stress disorder: the neurobiological impact of psychological trauma","volume":"13","author":"Sherin","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176329_bib58","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1021\/acschemneuro.3c00212","article-title":"DM506 (3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole fumarate), a novel derivative of ibogamine, inhibits alpha7 and alpha9alpha10 nicotinic acetylcholine receptors by different allosteric mechanisms","volume":"14","author":"Tae","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176329_bib59","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","article-title":"ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution","volume":"16","author":"Tian","year":"2020","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejphar.2024.176329_bib60","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3389\/fnins.2019.00404","article-title":"Overcoming resistance to selective serotonin reuptake inhibitors: targeting serotonin, serotonin-1A receptors and adult neuroplasticity","volume":"13","author":"Vahid-Ansari","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176329_bib61","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176329_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2010.00036","article-title":"Htr2a gene and 5-ht2a receptor expression in the cerebral cortex studied using genetically modified mice","author":"Weber","year":"2010","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176329_bib63","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jcc.23702","article-title":"CHARMM-GUI Membrane Builder toward realistic biological membrane simulations","volume":"35","author":"Wu","year":"2014","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924000177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924000177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:26:12Z","timestamp":1757978772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924000177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":63,"alternative-id":["S0014299924000177"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176329","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT2A receptor activation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"176329"}}